Home
Clinical Trials
A Phase II Clinical Trial on ...

A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

Last Updated: 2026-01-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

195 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-22

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT06527144

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

NCT07147946

Chronic Obstructive Pulmonary Disease

NOT_YET_RECRUITING PHASE3

A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease

NCT06748079

Chronic Obstructive Pulmonary Disease (COPD)

RECRUITING PHASE1

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

NCT05292196

Chronic Obstructive Pulmonary Disease (COPD)

TERMINATED PHASE2

A Clinical Trial of TQC3721 Suspension for Inhalation

NCT05051930

Chronic Obstructive Pulmonary Disease

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

750 µg Dosage group

750 µg TQC3721 inhalation powder，administered by inhalation，twice a day for 4 weeks.

Group Type EXPERIMENTAL

TQC3721 inhalation powder

Intervention Type DRUG

TQC3721 inhalation powder is target inhibitor.

1000 µg Dosage group

1000µg TQC3721 inhalation powder，administered by inhalation，twice a day for 4 weeks.

Group Type EXPERIMENTAL

TQC3721 inhalation powder

Intervention Type DRUG

TQC3721 inhalation powder is target inhibitor.

Placebo for TQC3721 inhalation powder

Placebo for TQC3721 inhalation powder, administered by inhalation, twice a day for 4 weeks.

Group Type PLACEBO_COMPARATOR

Placebo for TQC3721 inhalation powder

Intervention Type DRUG

Placebo for TQC3721 inhalation powder.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TQC3721 inhalation powder

TQC3721 inhalation powder is target inhibitor.

Intervention Type DRUG

Placebo for TQC3721 inhalation powder

Placebo for TQC3721 inhalation powder.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sign the informed consent form before the trial and have a full understanding of the trial content, process, and potential adverse reactions.
* Be willing and able to adhere to the trial visit schedule and procedures and use the dry powder inhaler correctly.
* Male and female subjects aged 40 to 80 years (inclusive).
* Body Mass Index (BMI) within the range of 18-30 kg/m² (inclusive).
* Subjects have no plans for pregnancy and voluntarily adopt effective contraceptive measures from screening to at least 1 month after the last use of the study drug.
* 12-lead electrocardiogram (ECG) showing: heart rate of 50-100 beats per minute (bpm); corrected QT interval (QTcF) \<= 450 msec for males or \<= 470 msec for females; Q wave, R wave, S wave (QRS) interval \<= 120 msec.
* Diagnosed with COPD according to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and have had symptoms consistent with COPD for at least 1 year before screening.
* Have been on stable background inhaled therapy for COPD for at least 4 weeks before screening.
* Be able to perform acceptable and reproducible pulmonary function tests.
* At the screening visit (V1 visit), after administration of a bronchodilator (4 puffs of salbutamol), the FEV1/Forced Vital Capacity (FVC) ratio \< 0.7, and 30% predicted value \<= FEV1 \< 80% predicted value.
* Clinically stable COPD within 4 weeks before the screening visit (V1 visit) and between the V1 visit and V2 visit.
* Modified Medical Research Council (mMRC) Dyspnea Scale score \>= 2 at screening.
* Meet the concurrent medication restrictions (within the time intervals specified in the protocol) and are expected to maintain the restriction requirements during treatment.
* Smoking history \>= 10 pack-years (pack-year: number of packs per day × number of smoking years; e.g., 1 pack (20 cigarettes) per day for 10 consecutive years, or 10 cigarettes per day for 20 consecutive years).

Exclusion Criteria

* Life-threatening COPD history, including admission to the intensive care unit (ICU) and/or requirement for intubation.
* COPD exacerbation requiring systemic corticosteroid therapy within 3 months before the screening visit (V1 visit) or before the randomization visit (V2 visit).
* Hospitalization history due to COPD or pneumonia ≥ 1 time within 6 months before screening.
* Antibiotic treatment for upper and/or lower respiratory tract infections within 6 weeks before screening or before the randomization visit (V3 visit). Note: Subjects with a history of lower respiratory tract infection within 6 weeks cannot be enrolled, but may be rescreened 6 weeks after recovery from the infection.
* Concurrent other respiratory diseases: α-1 antitrypsin deficiency, primary ciliary dyskinesia, lung cancer; clinically significant active pulmonary infections, pulmonary tuberculosis, bronchiectasis, pulmonary fibrosis, sarcoidosis, pulmonary hypertension, asthma, and other respiratory diseases as assessed by the investigator.
* Clinically significant abnormalities found on chest computed tomography (CT) that are not caused by COPD and judged by the investigator to have an impact on trial results or patient safety. If there is no chest CT report within 6 months before Visit 1, a chest CT examination must be performed at Visit 1.
* Previous pulmonary resection or lung volume reduction surgery.
* Pulmonary rehabilitation therapy (those whose treatment has been stable for 4 weeks before screening and will remain stable during the trial may be enrolled).
* Receipt of oral corticosteroids or roflumilast for COPD within 3 months before the screening visit (V1 visit), or receipt of oral theophylline and/or theophylline derivatives for COPD within 1 week before the screening visit (V1 visit).
* Use of non-selective oral beta-blockers.
* Previous treatment with TQC3721.
* Patients who received immunotherapy (e.g., azathioprine, cyclophosphamide) within 4 weeks before the screening period.
* As assessed by the investigator, the patient cannot discontinue the prohibited drugs specified in the protocol during the screening and treatment phases of this study.
* The patient has a history of currently uncontrolled diseases, including but not limited to endocrine, thyroid, neuropsychiatric, hepatic, gastrointestinal, renal, hematologic, urinary, immunologic, or ophthalmic diseases, which are judged to be clinically significant by the investigator.
* History or current evidence of clinically significant cardiovascular diseases, defined as any disease that the investigator believes would endanger the patient's safety if participating in the study, or any disease that may affect the efficacy or safety analysis if the disease/condition deteriorates during the study; subjects with any of the following conditions at Visit 1 will be excluded:

1. Myocardial infarction, unstable angina, or stroke within the past 6 months;
2. Unstable or life-threatening arrhythmias requiring intervention within the past 3 months;
3. New York Heart Association (NYHA) Class III-IV heart failure.
* Unstable or uncontrolled hypertension (systolic blood pressure \>= 160 mmHg and diastolic blood pressure \>= 100 mmHg after drug control).
* Patients with poorly controlled type 2 diabetes or fasting blood glucose \> 10 mmol/L.
* Receipt of major surgery (requiring general anesthesia) within 8 weeks before the screening visit (V1 visit), failure to fully recover from the surgery at the time of screening (V1 visit), or planned surgery before the end of the study.
* History of malignant tumors (cured or uncured) of any organ or system within the past 5 years (excluding non-metastatic cutaneous basal cell or squamous cell carcinoma, or cervical carcinoma in situ that have been cured for more than 5 years before the screening period).
* Clinically significant abnormal values in safety laboratory tests (hematology, biochemistry, or urinalysis) determined by the investigator at the screening visit (V1 visit), including but not limited to one of the following:

1. Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 2 × Upper Limit of Normal (ULN); alkaline phosphatase \> 2 × ULN; total bilirubin \> 1.5 × ULN;
2. Estimated glomerular filtration rate (eGFR) calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \< 60 mL/min/1.73m².
* Positive test result for Human Immunodeficiency Virus (HIV) antibody; positive test result for Hepatitis B Surface Antigen (HBsAg) (if HBsAg is positive, Hepatitis B Virus (HBV) DNA testing may be added if necessary; subjects with HBV DNA \< Lower Limit of Quantification (LLOQ) need not be excluded); positive Hepatitis C Virus (HCV) antibody with confirmed presence of HCV ribonucleic acid (RNA); positive Treponema Pallidum Particle Agglutination (TPPA) antibody.
* Intolerance or allergy to salbutamol or other inhaled bronchodilator therapies for COPD.
* Patients requiring continuous or intermittent oxygen therapy.
* Female subjects who are pregnant, lactating, or planning to become pregnant during the study enrollment period.
* Receipt of live attenuated vaccine within 28 days before randomization, receipt of inactivated vaccine within 7 days before randomization, or planned vaccination during the study.
* History of drug abuse or alcoholism within the past 3 years (consumption of 14 units of alcohol per week: 1 unit = 360 ml of beer, or 45 ml of spirits with 40% alcohol content, or 150 ml of wine).
* Participation in any drug or medical device clinical trial within 4 weeks or 5 drug half-lives (whichever is longer) before screening.
* Other conditions deemed unsuitable for study participation by the investigator.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.